comprehensive -WSS

comprehensive

author：leisure time 2025-09-28 00:49:42 - browse：5387

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： What causes osteoarthritis? Researchers study link to brain protein

WSS

The inclusion problem at the heart of rehabilitation research

Will an HIV vaccine ever be a reality?

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Printout prescription drug information shouldn’t go digital

Health insurers' Q3 question: how much care are people getting?

Experts study whether long Covid risk adds up with each reinfection

leisure time

comprehensive

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Maisha Meds is a PBM, but don't call it that

Apple is now the first public company to be valued at $3 trillion

CVS is on a mission to consolidate health care. Will it work?

Moonlake's readout produced a cash windfall. Risks remain

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Medical records are filled with copy

Congress extends some pandemic preparedness programs

Medicare proposal to cover medical devices draws a mixed reaction

The United States is paying nearly triple for new Covid vaccines

focus

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Printout prescription drug information shouldn’t go digital

Medicare bonuses could stop drug shortages under Senate plan

The Karikó problem: Lessons for funding basic research

Mass General, Mayo Clinic look to monetize custom

CVS is on a mission to consolidate health care. Will it work?

focus

focus

leisure time

Wikipedia